QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)

Genelux Stock Price, News & Analysis (NASDAQ:GNLX)

$10.46
-0.41 (-3.77%)
(As of 11/28/2023 ET)
Compare
Today's Range
$10.28
$11.16
50-Day Range
$10.38
$28.77
52-Week Range
$5.35
$40.98
Volume
115,415 shs
Average Volume
127,583 shs
Market Capitalization
$279.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.00

Genelux MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
234.6% Upside
$35.00 Price Target
Short Interest
Healthy
4.07% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.16mentions of Genelux in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$8.74 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.03) to ($0.60) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.24 out of 5 stars

Medical Sector

350th out of 949 stocks

Biotechnology Industry

4th out of 19 stocks


GNLX stock logo

About Genelux Stock (NASDAQ:GNLX)

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1, an animal health product candidate. It has a licensing agreement with ELIAS Animal Health, LLC. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.

GNLX Stock Price History

GNLX Stock News Headlines

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Genelux (NASDAQ:GNLX) PT Lowered to $30.00
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Genelux VP Sold $191K In Company Stock
Genelux GAAP EPS of -$0.20 misses by $0.02
Genelux Corp GNLX
10% Owner of Genelux Makes $110K Sale
Genelux Insider Trades Send a Signal
VP at Genelux Exercises Options Worth $97K
Genelux 10% Owner Trades Company's Stock
Genelux Recent Insider Activity
Genelux 10% Owner Sold $1.03M In Company Stock
See More Headlines
Receive GNLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genelux and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
11/28/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/13/2024

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GNLX
Fax
N/A
Employees
22
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$35.00
High Stock Price Target
$40.00
Low Stock Price Target
$30.00
Potential Upside/Downside
+234.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-5,210,000.00
Pretax Margin
-10,514.71%

Debt

Sales & Book Value

Annual Sales
$11.07 million
Book Value
($1.51) per share

Miscellaneous

Free Float
23,592,000
Market Cap
$279.49 million
Optionable
Not Optionable
Beta
N/A
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Thomas Zindrick J.D. (Age 64)
    Chairman, CEO & President
    Comp: $500k
  • Mr. Sean Ryder J.D. (Age 54)
    General Counsel & Corporate Secretary
    Comp: $380k
  • Ms. Lourie S. Zak (Age 60)
    CFO & Principal Accounting Officer
  • Dr. Joseph Cappello Ph.D. (Age 66)
    Chief Technical Officer
    Comp: $213.08k
  • Dr. Yong Yu Ph.D. (Age 52)
    Senior Vice President of Clinical Development
    Comp: $242.62k
  • Prof. Paul Scigalla M.D. (Age 77)
    Ph.D., Chief Medical Officer
  • Mr. Ralph Smalling B.Sc. (Age 67)
    Head of Regulatory Affairs
  • Ms. Caroline Jewett (Age 59)
    Head of Quality














GNLX Stock Analysis - Frequently Asked Questions

Should I buy or sell Genelux stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genelux in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GNLX shares.
View GNLX analyst ratings
or view top-rated stocks.

What is Genelux's stock price target for 2024?

4 Wall Street research analysts have issued twelve-month price targets for Genelux's stock. Their GNLX share price targets range from $30.00 to $40.00. On average, they expect the company's stock price to reach $35.00 in the next year. This suggests a possible upside of 234.6% from the stock's current price.
View analysts price targets for GNLX
or view top-rated stocks among Wall Street analysts.

How have GNLX shares performed in 2023?

Genelux's stock was trading at $6.01 at the beginning of 2023. Since then, GNLX stock has increased by 74.0% and is now trading at $10.46.
View the best growth stocks for 2023 here
.

Are investors shorting Genelux?

Genelux saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 789,200 shares, a decrease of 8.8% from the October 31st total of 865,800 shares. Based on an average daily volume of 228,700 shares, the days-to-cover ratio is presently 3.5 days. Currently, 4.1% of the company's shares are short sold.
View Genelux's Short Interest
.

When is Genelux's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 13th 2024.
View our GNLX earnings forecast
.

When did Genelux IPO?

(GNLX) raised $16 million in an IPO on Thursday, January 26th 2023. The company issued 2,500,000 shares at a price of $6.00-$7.00 per share. The Benchmark Company and Brookline Capital Markets acted as the underwriters for the IPO.

Who are Genelux's major shareholders?

Genelux's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Provident Wealth Management LLC (1.36%), AE Wealth Management LLC (0.79%), Northern Trust Corp (0.61%), Charles Schwab Investment Management Inc. (0.56%), Bank of New York Mellon Corp (0.22%) and AMG National Trust Bank (0.19%). Insiders that own company stock include Aladar Szalay, Caroline Jewett, Doug Samuelson, John Thomas, John W Smither, Joseph Cappello, Qian Zhang, Sean Ryder, Thomas Zindrick and Yong Yu.
View institutional ownership trends
.

How do I buy shares of Genelux?

Shares of GNLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:GNLX) was last updated on 11/28/2023 by MarketBeat.com Staff

My Account -